It is used as a pharmaceutical intermediate.
Morihiro Mitsuya.; Kensuke Kobayashi.; Kumiko Kawakami.; Atsushi Satoh.; Yoshio Ogino.; Taro Kakikawa.; Norikazu Ohtake.; Toshifumi Kimura.; Hiroyasu Hirose.; Akio Sato.; Tomosige Numazawa.;Takuro Hasegawa.; Kazuhito Noguchi.; Toshiaki Mase. A Potent, Long-Acting, Orally Active (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide:? A Novel Muscarinic M3 Receptor Antagonist with High Selectivity for M3 over M2 Receptors. J. Med. Chem. 2000, 43 (26),5017-5029.
Evan G. Robertson.; Matthew R. Hockridge.; Peter D. Jelfsa.; John P. Simons. IR-UV ion-depletion and fluorescence spectroscopy of2-phenylacetamide clusters: hydration of a primary amide. Phys. Chem. Chem. Phys. 2001, 3 (5),786-795.
Mentions de danger (UE): H302-H319
Harmful if swallowed. Causes serious eye irritation.
Mentions de prudence: P260-P201-P280i-P304+P340-P405-P501a
Do not breathe dust/fume/gas/mist/vapours/spray. Obtain special instructions before use. Wear eye/face protection. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.